Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 5-(3-((1,4-benzodioxan-2-ylmethyl)amino)propoxy)-1,3-benzodioxole Hydrochloride
2. Mkc 242
3. Mkc-242
4. Osemozotan
1. Osemozotan Hydrochloride
2. Osemozotan Hcl
3. 137275-80-0
4. Mkc-242
5. F0wkfypql8
6. 137275-80-0 (hcl)
7. Osemozotan (hydrochloride)
8. Mkc 242
9. 1,4-benzodioxin-2-methanamine, N-[3-(1,3-benzodioxol-5-yloxy)propyl]-2,3-dihydro-, Hydrochloride (1:1), (2s)-
10. Mci-242
11. 1,4-benzodioxin-2-methanamine, N-(3-(1,3-benzodioxol-5-yloxy)propyl)-2,3-dihydro-, Hydrochloride (1:1), (2s)-
12. 5-(3-((2s)-(1,4-benzodioxan-2-ylmethyl)amino)propoxy)-1,3-benzodioxol
13. Unii-f0wkfypql8
14. 1,4-benzodioxin-2-methanamine, 2,3-dihydro-n-(3-(1,3-benzodioxol-5-yloxy)propyl)-, Hydrochloride, (s)-
15. Schembl678900
16. Dtxsid00929762
17. Db05339
18. Hy-100426a
19. Cs-0018819
20. 3-(1,3-benzodioxol-5-yloxy)-n-[[(3s)-2,3-dihydro-1,4-benzodioxin-3-yl]methyl]propan-1-amine;hydrochloride
21. 3-[(2h-1,3-benzodioxol-5-yl)oxy]-n-[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]propan-1-amine--hydrogen Chloride (1/1)
22. 5-(3-((1,4-benzodioxan-2-ylmethyl)amino)propoxy)-1,3-benzodioxole Hydrochloride, S-
| Molecular Weight | 379.8 g/mol |
|---|---|
| Molecular Formula | C19H22ClNO5 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 7 |
| Exact Mass | 379.1186505 g/mol |
| Monoisotopic Mass | 379.1186505 g/mol |
| Topological Polar Surface Area | 58.2 Ų |
| Heavy Atom Count | 26 |
| Formal Charge | 0 |
| Complexity | 409 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
Investigated for use/treatment in anxiety disorders, depression, insomnia, and neurologic disorders.
MN-305 is a potent and highly-selective full agonist at the serotonin 5-HT1A receptor under development by MediciNova both for the treatment of insomnia, as well as for anxiety disorders such as Generalized Anxiety Disorder (GAD). MN-305 has been evaluated in an extensive preclinical toxicology program which showed no evidence of inducing genetic mutations, immune response or cancer. MN-305 has also proved to be consistently well-tolerated in clinical safety, efficacy and pharmacokinetic studies in over 1,200 subjects.
ABOUT THIS PAGE
A Osemozotan Hydrochloride manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Osemozotan Hydrochloride, including repackagers and relabelers. The FDA regulates Osemozotan Hydrochloride manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Osemozotan Hydrochloride API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Osemozotan Hydrochloride supplier is an individual or a company that provides Osemozotan Hydrochloride active pharmaceutical ingredient (API) or Osemozotan Hydrochloride finished formulations upon request. The Osemozotan Hydrochloride suppliers may include Osemozotan Hydrochloride API manufacturers, exporters, distributors and traders.
click here to find a list of Osemozotan Hydrochloride suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Osemozotan Hydrochloride DMF (Drug Master File) is a document detailing the whole manufacturing process of Osemozotan Hydrochloride active pharmaceutical ingredient (API) in detail. Different forms of Osemozotan Hydrochloride DMFs exist exist since differing nations have different regulations, such as Osemozotan Hydrochloride USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Osemozotan Hydrochloride DMF submitted to regulatory agencies in the US is known as a USDMF. Osemozotan Hydrochloride USDMF includes data on Osemozotan Hydrochloride's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Osemozotan Hydrochloride USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Osemozotan Hydrochloride suppliers with USDMF on PharmaCompass.
Osemozotan Hydrochloride Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Osemozotan Hydrochloride GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Osemozotan Hydrochloride GMP manufacturer or Osemozotan Hydrochloride GMP API supplier for your needs.
A Osemozotan Hydrochloride CoA (Certificate of Analysis) is a formal document that attests to Osemozotan Hydrochloride's compliance with Osemozotan Hydrochloride specifications and serves as a tool for batch-level quality control.
Osemozotan Hydrochloride CoA mostly includes findings from lab analyses of a specific batch. For each Osemozotan Hydrochloride CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Osemozotan Hydrochloride may be tested according to a variety of international standards, such as European Pharmacopoeia (Osemozotan Hydrochloride EP), Osemozotan Hydrochloride JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Osemozotan Hydrochloride USP).
LOOKING FOR A SUPPLIER?
